Irodalom:
1. de Vrese M, Schrezenmeir J.: Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol.
2008;111:1-66.
2. Oguz Resat Sipahi.: Economics of Antibiotic Resistance Expert Rev Anti Infect Ther. 2008;6(4):523-539.
3. Steed H, Macfarlane GT, Macfarlane S.: Prebiotics, synbiotics and inflammatory bowel disease. Mol
Nutr Food Res 2008 Aug;52(8):898-905.
4. Laukoetter MG, Nava P, Nusrat A.: Role of the intestinal barrier in inflammatory bowel disease. World
J Gastroenterol. 2008 Jan 21;14(3):401-7.
5. Fedorak RN.: Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol
2008 Sep;42 Suppl 3 Pt 1:S111-5.
6. Vanderpool C, Yan F, Polk DB.: Mechanisms of probiotic action: Implications for therapeutic applications
in inflammatory bowel diseases. Inflamm Bowel Dis. 2008 Nov;14(11):1585-96.
7. Oliver Brain; Simon P.L.: Travis Therapy of Ulcerative Colitis: State of the Art. Curr Opin Gastroenterol.
2008;24(4):469-474.
8. A. K. Akobeng Review Article: The Evidence Base for Interventions Used to Maintain Remission in
Crohn’s Disease. Aliment Pharmacol Ther. 2008;27(1):11-18.
9. Schultz M, Lindström AL.: Rationale for probiotic treatment strategies in inflammatory bowel disease.
Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):337-55.
10. M.A Kamm Review Article: New Drug Formulations, Chemical Entities and Therapeutic Approaches
for the Management of Ulcerative Colitis. Aliment Pharmacol Ther. 2008;28(7):815-829.
11. Lee JH, Lee B, Lee HS, Bae EA, Lee H, Ahn YT, Lim KS, Huh CS, Kim DH.: Lactobacillus suntoryeus
inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental
colitis. Int J Colorectal Dis. 2008 Dec 3. [Epub ahead of print]
12. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R.:
Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol.
2008 Sep;42 Suppl 3 Pt 2:S214-7.
13. Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB.: Effectiveness of Probiotics in the Treatment
of Irritable Bowel Syndrome. Pharmacotherapy. 2008;28(4):496-505.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 435
436 Gastro Update 2009
14. Spiller R.: Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol
Ther. 2008 Aug 15;28(4):385-96.
15. McFarland LV, Dublin S.: Meta-analysis of probiotics for the treatment of irritable bowel syndrome.
World J Gastroenterol. 2008 May 7;14(17):2650-61.
16. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH.: Effect of Active Lactic Acid Bacteria on Mucosal
Barrier Function in Patients With Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment Pharmacol
Ther. 2008;28(8):994-1002.
17. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.: A double blind
randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Gastroenterol Clin Biol 2008 Feb;32(2):147-52.
18. Williams E, Stimpson J, Wang D, Plummer S, Garaiova I, Barker M, Corfe B.: Clinical trial: a multistrain
probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind
placebo-controlled study. Aliment Pharmacol Ther. 2008 Sep 10. [Epub ahead of print]
19. Kajander K, Myllyluoma E, Rajiliæ-Stojanoviæ M, Kyrönpalo S, Rasmussen M, Jûrvenpûû S, Zoetendal
EG, de Vos WM, Vapaatalo H, Korpela R.: Clinical trial: multispecies probiotic supplementation
alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment
Pharmacol Ther. 2008;27(1):48-57.
20. Halsey J.: Current and future treatment modalities for Clostridium difficile-associated disease. Am J
Health Syst Pharm. 2008 Apr 15;65(8):705-15.
21. Doron SI, Hibberd PL, Gorbach SL.: Probiotics for prevention of antibiotic-associated diarrhea. J Clin
Gastroenterol. 2008 Jul;42 Suppl 2:S58-63.
22. Pillai A, Nelson R.: Probiotics for treatment of Clostridium difficile-associated colitis in adults.
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004611.
23. Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbrügger RW.: The effect of a
multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking
the antibiotic amoxycillin. Am J Gastroenterol 2008;103(1):178-89.
24. Ruszczyòski M, Radzikowski A, Szajewska H.: Clinical trial: effectiveness of Lactobacillus rhamnosus
(strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment
Pharmacol Ther. 2008 Jul;28(1):154-61.
25. Demeter P.:A probiotikumok alkalmazásának lehetõségei emésztõszervi betegségekben. LAM 2006;16(1):41-47.
26. Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP.: Lactobacillus acidophilus inhibits growth of
Campylobacter pylori in vitro. J Clin Microbiol 1989;27:2328-30.
27. Lorca GL, Wadstrom T, Valdez GF, Ljungh A.: Lactobacillus acidophilus autolysins inhibit Helicobacter
pylori in vitro. Curr Microbiol 2001;42:39-44.
28. Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F et al.: A lyophilized and inactivated
culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol
Ther 2000;14:1625-9.
29. Saad RJ, Chey WD.: Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy –
What’s Next? Clin Gastroenterol Hepatol. 2008;6(10):1086-1090.
30. Graham DY, Shiotani A.: New Concepts of Resistance in the Treatment of Helicobacter pylori Infections.
Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):321.
31. Zhang L, Su P, Henriksson A, O’Rourke J, Mitchell H.: Investigation of the immunomodulatory effects
of Lactobacillus casei and Bifidobacterium lactis on Helicobacter pylori infection. Helicobacter. 2008
Jun;13(3):183-90.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 436
Gyógyszerek, therápia 437
32. Myllyluoma E, Ahonen AM, Korpela R, Vapaatalo H, Kankuri E.: Effects of multispecies probiotic
combination on helicobacter pylori infection in vitro. Clin Vaccine Immunol. 2008 Sep;15(9):1472-82.
33. Imase K, Takahashi M, Tanaka A, Tokunaga K, Sugano H, Tanaka M, Ishida H, Kamiya S, Takahashi S.:
Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy
in relation to changes in the intestinal microbiota. Microbiol Immunol. 2008 Mar;52(3):156-61.
34. Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Maurogiovanni G, Bucci N, De Canio A,
Indrio F, Cavallo L, Ierardi E, Miniello VL.: Inhibition of Helicobacter pylori infection in humans by
Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008
Apr;13(2):127-34.
35. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS.:
The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008
Aug;13(4):261-8.
36. Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S.:
Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol
Sci. 2008;12(4):251-6.
37. Solga SF.: Probiotics can treat hepatic encephalopathy. Medical Hypotheses 2003;61:307-13.
38. O’Sullivan DJ.: Genomics can advance the potential for probiotic cultures to improve liver and overall
health. Curr Pharm Des. 2008;14(14):1376-81.
39. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R,
Sartor RB, Swanson C, Turner JR.: Alcohol, intestinal bacterial growth, intestinal permeability to
endotoxin, and medical consequences: summary of a symposium. Alcohol. 2008 Aug;42(5):349-61.
40. Jasmohan S Bajaj: Management Options for Minimal Hepatic Encephalopathy. Expert Rev Gastroenterol Hepatol.
2008;2(6):785-790.
41. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G,
Hoffmann RG, Binion DG.: Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J
Gastroenterol. 2008 Jul;103(7):1707-15.
42. Nicaise C, Prozzi D, Viaene E, Moreno C, Gustot T, Quertinmont E, Demetter P, Suain V, Goffin P,
Deviere J, Hols P.: Control of acute, chronic, and constitutive hyperammonemia by wild-type and
genetically engineered Lactobacillus plantarum in rodents. Hepatology. 2008 Oct;48(4):1184-92.
43. Vleggaar FP, Monkelbaan JF, van Erpecum KJ.: Probiotics in primary sclerosing cholangitis: a
randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):688-92.
44. Lazo M, Clark JM.: The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective.
Semin Liver Dis. 2008;28(4):339-350.
45. Oh MK, Winn J, Poordad F.: Review Article: Diagnosis and Treatment of Non-alcoholic Fatty Liver
Disease. Aliment Pharmacol Ther. 2008;28(5):503-522.
46. Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova F, UribM.: Intestinal flora, probiotics, and
cirrhosis. Ann Hepatol. 2008 Apr-Jun;7(2):120-4.
47. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G.: VSL#3 probiotic
treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic
steatohepatitis model in mice. Hepatology. 2008 Dec 29. [Epub ahead of print]
48. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R.: Effect of probiotic treatment
on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis.
J Hepatol. 2008 Jun;48(6):945-51.
